GlassScriptPhysician profile
Lana Gafter
NPI 1376529552
$1,753.47
in general payments reported to CMS, 2019-2025
13 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $86.00 · 2022: $48.79 · 2023: $77.92 · 2024: $632 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461 · Consulting Fee: $375 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225 · Education: $43.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.19 |
| Consulting Fee | $375.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
| Education | $43.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $375.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $353.22 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $257.47 | 2019 | |
| Nxstage Medical, INC. | $229.90 | 2024 | |
| Vifor Pharma, INC. | $174.77 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $111.20 | 2019-2020 | |
| Glaxosmithkline, LLC. | $48.79 | 2022 | |
| Aurinia Pharma U.S., INC. | $43.00 | 2023 | Lupkynis |
| Baxter Healthcare | $42.87 | 2019 | |
| Calliditas Therapeutics US INC. | $35.81 | 2025 | Tarpeyo |
| Ardelyx, INC. | $34.92 | 2023 | Ibsrela |
| Lilly USA, LLC | $32.34 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $14.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lana Gafter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.